首页 > 最新文献

Pediatric Hematology Oncology Journal最新文献

英文 中文
Pediatric mature B-cell non-hodgkin lymphoma in India: A retrospective multicenter pooled analysis of treatment approaches and outcomes 印度儿童成熟b细胞非霍奇金淋巴瘤:治疗方法和结果的回顾性多中心汇总分析
Pub Date : 2025-03-01 DOI: 10.1016/j.phoj.2024.11.104
Nirmalya Roy Moulik , Sameer Bakhshi , Shripad Banavali , Venkatraman Radhakrishnan , Amita Trehan , Anshul Gupta , Niharendu Ghara , Rachna Seth , Ramandeep Singh Arora

Background

Published data on outcomes of pediatric mature B-cell non-Hodgkin lymphoma (B-NHL) from India is limited and difficult to interpret due to small sample size and non-uniform treatment protocols. This study aims to do a pooled analysis of published patient data from multiple centers across India to provide a clearer understanding of survival rates and treatment-related toxicities with respect to the treatment protocols in this population.

Methods

A pooled analysis was conducted of patient data from 505 children with mature B-NHL, including Burkitt lymphoma (n = 395), diffuse large B-cell lymphoma (DLBCL, n = 52), and other subtypes (n = 58), treated from 2000 to 2022 at seven major cancer centers in India. Outcomes assessed were grade 3/4 toxicities, toxic deaths, relapse/progression, and survival rates.

Results

Most patients (401/505) presented with advanced disease; bone marrow and CNS involvement were observed in 13.9 % and 6.9 % of cases, respectively. Treatment protocols primarily included LMB (n = 208), BFM (n = 191), and MCP (n = 61). Grade 3/4 toxicities were reported in 79.2 % of patients, with higher rates observed with LMB protocol (92.1 %) compared to BFM (70.8 %) and MCP (70.1 %) (p < 0.001). Toxic death rates were similar across protocols. Overall survival (OS) and event-free survival (EFS) at a median follow-up of 17 months were 69.4 ± 2.2 % and 64.9 ± 2.2 %, respectively, with no significant differences in relapse/progression rates or stage-specific OS between protocols (p = 0.28 and 0.51).

Conclusions

This pooled analysis shows that although treatment-related toxicities differ by protocol, overall survival outcomes were similar across the LMB, BFM, and MCP regimens, despite being much lower than those reported from high income countries. Uniform standardized protocols may further improve outcomes for pediatric B-NHL in India.
背景:印度儿童成熟b细胞非霍奇金淋巴瘤(B-NHL)预后的已发表数据有限,且由于样本量小和治疗方案不统一,难以解释。本研究旨在对印度多个中心发表的患者数据进行汇总分析,以便更清楚地了解该人群中治疗方案的存活率和治疗相关毒性。方法对2000年至2022年在印度7个主要癌症中心治疗的505例成熟B-NHL患儿的患者数据进行汇总分析,包括Burkitt淋巴瘤(n = 395)、弥漫大b细胞淋巴瘤(DLBCL, n = 52)和其他亚型(n = 58)。评估的结果是3/4级毒性、中毒性死亡、复发/进展和生存率。结果401/505例患者以晚期疾病为主;累及骨髓和中枢神经系统分别占13.9%和6.9%。治疗方案主要包括LMB (n = 208)、BFM (n = 191)和MCP (n = 61)。79.2%的患者报告了3/4级毒性,LMB方案的发生率(92.1%)高于BFM(70.8%)和MCP (70.1%) (p <;0.001)。不同方案的毒性死亡率相似。中位随访17个月的总生存率(OS)和无事件生存率(EFS)分别为69.4±2.2%和64.9±2.2%,两种方案在复发/进展率或分期特异性OS方面无显著差异(p = 0.28和0.51)。该综合分析表明,尽管治疗相关毒性因方案而异,但LMB、BFM和MCP方案的总体生存结果相似,尽管远低于高收入国家报告的结果。统一的标准化方案可能进一步改善印度儿童B-NHL的预后。
{"title":"Pediatric mature B-cell non-hodgkin lymphoma in India: A retrospective multicenter pooled analysis of treatment approaches and outcomes","authors":"Nirmalya Roy Moulik ,&nbsp;Sameer Bakhshi ,&nbsp;Shripad Banavali ,&nbsp;Venkatraman Radhakrishnan ,&nbsp;Amita Trehan ,&nbsp;Anshul Gupta ,&nbsp;Niharendu Ghara ,&nbsp;Rachna Seth ,&nbsp;Ramandeep Singh Arora","doi":"10.1016/j.phoj.2024.11.104","DOIUrl":"10.1016/j.phoj.2024.11.104","url":null,"abstract":"<div><h3>Background</h3><div>Published data on outcomes of pediatric mature B-cell non-Hodgkin lymphoma (B-NHL) from India is limited and difficult to interpret due to small sample size and non-uniform treatment protocols. This study aims to do a pooled analysis of published patient data from multiple centers across India to provide a clearer understanding of survival rates and treatment-related toxicities with respect to the treatment protocols in this population.</div></div><div><h3>Methods</h3><div>A pooled analysis was conducted of patient data from 505 children with mature B-NHL, including Burkitt lymphoma (n = 395), diffuse large B-cell lymphoma (DLBCL, n = 52), and other subtypes (n = 58), treated from 2000 to 2022 at seven major cancer centers in India. Outcomes assessed were grade 3/4 toxicities, toxic deaths, relapse/progression, and survival rates.</div></div><div><h3>Results</h3><div>Most patients (401/505) presented with advanced disease; bone marrow and CNS involvement were observed in 13.9 % and 6.9 % of cases, respectively. Treatment protocols primarily included LMB (n = 208), BFM (n = 191), and MCP (n = 61). Grade 3/4 toxicities were reported in 79.2 % of patients, with higher rates observed with LMB protocol (92.1 %) compared to BFM (70.8 %) and MCP (70.1 %) (p &lt; 0.001). Toxic death rates were similar across protocols. Overall survival (OS) and event-free survival (EFS) at a median follow-up of 17 months were 69.4 ± 2.2 % and 64.9 ± 2.2 %, respectively, with no significant differences in relapse/progression rates or stage-specific OS between protocols (p = 0.28 and 0.51).</div></div><div><h3>Conclusions</h3><div>This pooled analysis shows that although treatment-related toxicities differ by protocol, overall survival outcomes were similar across the LMB, BFM, and MCP regimens, despite being much lower than those reported from high income countries. Uniform standardized protocols may further improve outcomes for pediatric B-NHL in India.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"10 1","pages":"Pages 33-40"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143697553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ewing sarcoma of the hands and feet: Outcome and prognostic factors of a rare subsite in a low-middle income country 手和脚的尤文氏肉瘤:在中低收入国家的一种罕见亚位点的结局和预后因素
Pub Date : 2025-03-01 DOI: 10.1016/j.phoj.2025.02.004
Shuvadeep Ganguly , Archana Sasi , Chitrakshi Nagpal , Bivas Biswas , Sandeep Agarwala , Deepam Pushpam , Ahitagni Biswas , Venkatesan Sampath Kumar , Love Kapoor , Shah Alam Khan , Vishesh Jain , Sameer Bakhshi

Background

The small bones of the hand and feet represent a rare site of Ewing sarcoma (ES) origin. This study presents a real-world dataset describing the clinical presentation, survival outcomes, and their determinants in this subsite.

Methods

This is a single-institutional retrospective study of patients with ES originating from the hands/feet (ES-HF), treated between 2003 and 2018. Clinical/demographic details and survival outcomes were retrieved from medical records. Descriptive statistics were used to summarize baseline characteristics. Prognostic factors for event-free survival (EFS) and overall survival (OS) were identified by Cox regression. The clinical features and outcomes were compared between ES-HF and ES-others (ES from other sites) in the cohort.

Results

Of 859 ES cases, 28 (3.2 %) patients had ES-HF including four ES-hands (0.5 %) and 24 ES-feet (2.8 %). The calcaneum was the most common site [11 of 28 cases; 39.3 %]. More than half of the patients (53.6 %) had metastatic disease at presentation. In comparison with ES-others, ES-HF had longer median symptom duration [12 versus 4 months; p < 0.001] and smaller tumor diameter [5.5 versus 9 cm; p < 0.001]. The median EFS and OS of the cohort were 30.5 and 39.13 months respectively. Only local therapy receipt was associated with improved EFS (multivariable HR:0.013; 95%CI:0.001–0.158; p < 0.001) and OS (multivariable HR:0.028; 95 % CI:0.003–0.272; p = 0.002). Patients receiving radiotherapy alone had inferior OS compared to those receiving surgery alone. (HR: 9.22; 95 % CI: 1.12–76.31; p = 0.039)

Conclusion

ES-HF is a rare ES subsite. Although indolent, metastases are common at presentation. Meticulous local control can improve survival in both localized and metastatic disease for this subsite.
背景:手和脚的小骨是罕见的尤文氏肉瘤(ES)起源部位。本研究提供了一个真实世界的数据集,描述了该亚位点的临床表现、生存结果及其决定因素。方法:这是一项单机构回顾性研究,研究对象是2003年至2018年间接受治疗的源自手/足ES (ES- hf)患者。从医疗记录中检索临床/人口统计学细节和生存结果。描述性统计用于总结基线特征。通过Cox回归确定无事件生存期(EFS)和总生存期(OS)的预后因素。比较ES- hf和ES-others(来自其他部位的ES)的临床特征和结果。结果859例ES患者中有28例(3.2%)合并ES- hf,包括4例ES-手(0.5%)和24例ES-足(2.8%)。跟骨是最常见的部位[28例中有11例;39.3%)。超过一半的患者(53.6%)在发病时有转移性疾病。与ES-others相比,ES-HF的中位症状持续时间更长[12个月对4个月;p & lt;0.001]和较小的肿瘤直径[5.5 vs . 9 cm;p & lt;0.001]。该队列的中位EFS和OS分别为30.5和39.13个月。只有局部治疗接受与改善的EFS相关(多变量HR:0.013;95%置信区间:0.001—-0.158;p & lt;0.001)和OS(多变量HR:0.028;95% ci: 0.003-0.272;p = 0.002)。单独接受放疗的患者的OS低于单独接受手术的患者。(人力资源:9.22;95% ci: 1.12-76.31;p = 0.039)结论ES- hf是罕见的ES亚位点。虽然是惰性的,但在出现时转移是常见的。细致的局部控制可以提高该亚位点的局部和转移性疾病的生存率。
{"title":"Ewing sarcoma of the hands and feet: Outcome and prognostic factors of a rare subsite in a low-middle income country","authors":"Shuvadeep Ganguly ,&nbsp;Archana Sasi ,&nbsp;Chitrakshi Nagpal ,&nbsp;Bivas Biswas ,&nbsp;Sandeep Agarwala ,&nbsp;Deepam Pushpam ,&nbsp;Ahitagni Biswas ,&nbsp;Venkatesan Sampath Kumar ,&nbsp;Love Kapoor ,&nbsp;Shah Alam Khan ,&nbsp;Vishesh Jain ,&nbsp;Sameer Bakhshi","doi":"10.1016/j.phoj.2025.02.004","DOIUrl":"10.1016/j.phoj.2025.02.004","url":null,"abstract":"<div><h3>Background</h3><div>The small bones of the hand and feet represent a rare site of Ewing sarcoma (ES) origin. This study presents a real-world dataset describing the clinical presentation, survival outcomes, and their determinants in this subsite.</div></div><div><h3>Methods</h3><div>This is a single-institutional retrospective study of patients with ES originating from the hands/feet (ES-HF), treated between 2003 and 2018. Clinical/demographic details and survival outcomes were retrieved from medical records. Descriptive statistics were used to summarize baseline characteristics. Prognostic factors for event-free survival (EFS) and overall survival (OS) were identified by Cox regression. The clinical features and outcomes were compared between ES-HF and ES-others (ES from other sites) in the cohort.</div></div><div><h3>Results</h3><div>Of 859 ES cases, 28 (3.2 %) patients had ES-HF including four ES-hands (0.5 %) and 24 ES-feet (2.8 %). The calcaneum was the most common site [11 of 28 cases; 39.3 %]. More than half of the patients (53.6 %) had metastatic disease at presentation. In comparison with ES-others, ES-HF had longer median symptom duration [12 versus 4 months; p &lt; 0.001] and smaller tumor diameter [5.5 versus 9 cm; p &lt; 0.001]. The median EFS and OS of the cohort were 30.5 and 39.13 months respectively. Only local therapy receipt was associated with improved EFS (multivariable HR:0.013; 95%CI:0.001–0.158; p &lt; 0.001) and OS (multivariable HR:0.028; 95 % CI:0.003–0.272; p = 0.002). Patients receiving radiotherapy alone had inferior OS compared to those receiving surgery alone. (HR: 9.22; 95 % CI: 1.12–76.31; p = 0.039)</div></div><div><h3>Conclusion</h3><div>ES-HF is a rare ES subsite. Although indolent, metastases are common at presentation. Meticulous local control can improve survival in both localized and metastatic disease for this subsite.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"10 1","pages":"Pages 24-32"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143683014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cefiderocol for severe bloodstream infection by multidrug-resistant Klebsiella pneumoniae in a pediatric patient with acute myeloid leukemia 头孢地罗治疗急性髓性白血病患儿多重耐药肺炎克雷伯菌严重血流感染
Pub Date : 2025-03-01 DOI: 10.1016/j.phoj.2025.02.003
Francesco De Leonardis , Francesca Marasciulo , Roberta Koronica , Mariachiara Servedio , Enza Pentassuglia , Vittorio Greco Miani , Lidia Dalfino , Stefania Stolfa , Nicola Santoro
{"title":"Cefiderocol for severe bloodstream infection by multidrug-resistant Klebsiella pneumoniae in a pediatric patient with acute myeloid leukemia","authors":"Francesco De Leonardis ,&nbsp;Francesca Marasciulo ,&nbsp;Roberta Koronica ,&nbsp;Mariachiara Servedio ,&nbsp;Enza Pentassuglia ,&nbsp;Vittorio Greco Miani ,&nbsp;Lidia Dalfino ,&nbsp;Stefania Stolfa ,&nbsp;Nicola Santoro","doi":"10.1016/j.phoj.2025.02.003","DOIUrl":"10.1016/j.phoj.2025.02.003","url":null,"abstract":"","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"10 1","pages":"Pages 57-58"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges faced in screening for thalassemia and other hemoglobinopathies in a North Indian population 北印度人口地中海贫血和其他血红蛋白病筛查面临的挑战
Pub Date : 2025-03-01 DOI: 10.1016/j.phoj.2025.02.005
Manisha Kumar, Vani Kargwal, Rajeev Goel, Ekta Debnath, Seema Malhotra, Kirti Balyan, Mahrukh Zaidi, Reena Yadav

Background

Hemoglobinopathies are a common group of inherited disorders contributing significantly to the global healthcare burden, particularly in low and middle-income countries (LMICs) such as India.

Objective

This prospective cross-sectional study aimed to investigate the epidemiological, clinical, and genetic aspects of hemoglobinopathies in the antenatal population attending a tertiary care hospital in Delhi.

Material and method

A total of 7077 antenatal women were investigated over four years, revealing an overall prevalence of Beta Thalassemia Trait (BTT) of 4.55%. The screening algorithm involved a complete blood count (CBC) and High Performance Liquid Chromatography (HPLC) for all the women, followed by mutation testing using Multiplex amplification refractory mutation system - polymerase chain reaction (ARMS PCR) for four common mutations: IVS1-5 (G > C), CD41/42 -TTCT, CD8/9 +G, and Del 619 bp. Multiplex ligation dependent probe amplification assay (MLPA), ARMS PCR and Sanger sequencing were used to identify other mutations. In cases where abnormal High Peformance Liquid Chromatography (HPLC) results were found, further testing of the husband was conducted to guide counselling and decisions regarding prenatal testing.

Results

IVS1-5 (G > C) was identified as the most common mutation. Hemoglobin E (HbE) with CD26 (G > A) exhibited the highest hemoglobin and HbA2 values amongst all mutations screened for. The study underscores the challenges of using RBC indices to diagnose BTT, due to marked overlap with Nutritional Deficiency Anemia (NDA). Similar issues were observed with HbD and HbE due to their relatively high MCV and MCH values. An algorithm for antenatal screening and diagnosis for LMIC is proposed but, given these caveats, its value remains to be proven.

Conclusion

The study provides data on the relative distribution of hemoglobinopathy mutations in the antenatal population in North India, and revealed the problems of detecting BTT or hemoglobinopathy in this population with a CBC due to the widespread prevalence of NDA. It emphasized the challenges of targeted screening strategies and genetic counselling to effectively reduce the prevalence of thalassemia in North India.
背景血红蛋白病是一组常见的遗传性疾病,严重加重了全球医疗负担,尤其是在印度等中低收入国家。这项前瞻性横断面研究旨在调查在德里一家三级医院就诊的产前人群中血红蛋白病的流行病学、临床和遗传学方面的情况。筛查算法包括对所有产妇进行全血细胞计数(CBC)和高效液相色谱法(HPLC)检查,然后使用多重扩增难治性突变系统-聚合酶链反应(ARMS PCR)对四种常见突变进行突变检测:IVS1-5 (G > C)、CD41/42 -TTCT、CD8/9 +G 和 Del 619 bp。多重连接依赖性探针扩增分析(MLPA)、ARMS PCR 和 Sanger 测序用于鉴定其他突变。如果发现高效液相色谱(HPLC)结果异常,则对丈夫进行进一步检测,以指导咨询和产前检测决策。血红蛋白 E (HbE) 与 CD26 (G > A) 的血红蛋白和 HbA2 值在所有筛查出的突变中最高。由于与营养缺乏性贫血(NDA)明显重叠,该研究强调了使用红细胞指数诊断 BTT 所面临的挑战。由于 HbD 和 HbE 的 MCV 和 MCH 值相对较高,因此也发现了类似的问题。该研究提供了北印度产前人群中血红蛋白病突变相对分布的数据,并揭示了由于 NDA 的广泛流行,在该人群中使用全血细胞计数检测 BTT 或血红蛋白病所存在的问题。它强调了有针对性的筛查策略和遗传咨询对有效降低北印度地中海贫血患病率的挑战。
{"title":"Challenges faced in screening for thalassemia and other hemoglobinopathies in a North Indian population","authors":"Manisha Kumar,&nbsp;Vani Kargwal,&nbsp;Rajeev Goel,&nbsp;Ekta Debnath,&nbsp;Seema Malhotra,&nbsp;Kirti Balyan,&nbsp;Mahrukh Zaidi,&nbsp;Reena Yadav","doi":"10.1016/j.phoj.2025.02.005","DOIUrl":"10.1016/j.phoj.2025.02.005","url":null,"abstract":"<div><h3>Background</h3><div>Hemoglobinopathies are a common group of inherited disorders contributing significantly to the global healthcare burden, particularly in low and middle-income countries (LMICs) such as India.</div></div><div><h3>Objective</h3><div>This prospective cross-sectional study aimed to investigate the epidemiological, clinical, and genetic aspects of hemoglobinopathies in the antenatal population attending a tertiary care hospital in Delhi.</div></div><div><h3>Material and method</h3><div>A total of 7077 antenatal women were investigated over four years, revealing an overall prevalence of Beta Thalassemia Trait (BTT) of 4.55%. The screening algorithm involved a complete blood count (CBC) and High Performance Liquid Chromatography (HPLC) for all the women, followed by mutation testing using Multiplex amplification refractory mutation system - polymerase chain reaction (ARMS PCR) for four common mutations: IVS1-5 (G &gt; C), CD41/42 -TTCT, CD8/9 +G, and Del 619 bp. Multiplex ligation dependent probe amplification assay (MLPA), ARMS PCR and Sanger sequencing were used to identify other mutations. In cases where abnormal High Peformance Liquid Chromatography (HPLC) results were found, further testing of the husband was conducted to guide counselling and decisions regarding prenatal testing.</div></div><div><h3>Results</h3><div>IVS1-5 (G &gt; C) was identified as the most common mutation. Hemoglobin E (HbE) with CD26 (G &gt; A) exhibited the highest hemoglobin and HbA2 values amongst all mutations screened for. The study underscores the challenges of using RBC indices to diagnose BTT, due to marked overlap with Nutritional Deficiency Anemia (NDA). Similar issues were observed with HbD and HbE due to their relatively high MCV and MCH values. An algorithm for antenatal screening and diagnosis for LMIC is proposed but, given these caveats, its value remains to be proven.</div></div><div><h3>Conclusion</h3><div>The study provides data on the relative distribution of hemoglobinopathy mutations in the antenatal population in North India, and revealed the problems of detecting BTT or hemoglobinopathy in this population with a CBC due to the widespread prevalence of NDA. It emphasized the challenges of targeted screening strategies and genetic counselling to effectively reduce the prevalence of thalassemia in North India.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"10 1","pages":"Pages 59-65"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current management of pulmonary relapse in Ewing sarcoma: A report from the Pediatric Surgical Oncology Research Collaborative 目前尤文氏肉瘤肺部复发的处理:一份来自儿科外科肿瘤研究协进会的报告
Pub Date : 2025-03-01 DOI: 10.1016/j.phoj.2024.11.105
Audra J. Reiter , Lynn Huang , Jennifer H. Aldrink , Brian T. Craig , Andrew M. Davidoff , Lindsay J. Talbot , Jordan Coggins , Jasmine Smith , Katherine C. Bergus , Taleen A. MacArthur , Stephanie F. Polites , Roshni Dasgupta , Chloe Boehmer , Joseph Brungardt , Marcus M. Malek , Hannah N. Rinehardt , Zachary J. Kastenberg , Cameron M. Arkin , Antoine Gourmel , Nelson Piche , Timothy B. Lautz

Background

Relapse occurs in 30–40 % of patients with localized Ewing sarcoma (EWS). Our objective was to describe the current management and outcomes of patients with initially localized EWS who experience first pulmonary relapse.

Methods

This multi-center retrospective cohort study included patients ≤22 years old with initially localized EWS treated from 2007 to 2020 at 19 Pediatric Surgical Oncology Research Collaborative institutions, who developed pulmonary relapse. Kaplan-Meier analysis was performed.

Results

Thirty-three patients with initially localized EWS developed pulmonary relapse at a median age of 17 (IQR 14; 20) years. Eleven (33 %) patients also had extra-pulmonary metastases (EPM) at relapse. Among the 22 (67 %) patients with pulmonary-only relapse, 10 (45 %) had solitary pulmonary nodules. Pulmonary metastasectomy was performed in 8/10 (80 %) patients with solitary pulmonary-only metastases, 5/12 (42 %) patients with multiple pulmonary-only metastases, and 2/11 (18 %) patients who also had EPM. Whole lung irradiation was administered in 7/10 (70 %) with solitary pulmonary-only metastases, 7/12 (58 %) with multiple pulmonary-only metastases, and 2/11 (18 %) with EPM. Rates of further pulmonary relapse/progression were similar between groups (p = 0.97). In Kaplan-Meier analysis, 3-year overall survival was 73 % with solitary pulmonary-only metastases, 40 % with multiple pulmonary-only metastases, and 23 % with EPM (p = 0.097).

Conclusions

While survival for patients with relapsed EWS is poor, the subset of patients with solitary relapse confined to the lung are often good candidates for pulmonary metastasectomy and have a non-statistically significant trend towards improved survival outcomes.
背景:30 - 40%的局部尤文氏肉瘤(EWS)患者复发。我们的目的是描述首次肺部复发的局部EWS患者的当前管理和结果。方法本多中心回顾性队列研究纳入了19家儿科外科肿瘤研究合作机构2007年至2020年治疗的≤22岁的原发性局限性EWS患者,这些患者发生肺部复发。进行Kaplan-Meier分析。结果33例初始局限性EWS患者发生肺部复发,中位年龄为17岁(IQR 14;20年。11例(33%)患者复发时也有肺外转移(EPM)。在22例(67%)单纯肺部复发的患者中,10例(45%)有孤立性肺结节。8/10(80%)单发肺转移患者行肺转移切除术,5/12(42%)多发肺转移患者行肺转移切除术,2/11(18%)合并EPM患者行肺转移切除术。单纯肺转移患者7/10(70%)、多发肺转移患者7/12(58%)、EPM患者2/11(18%)接受全肺照射。两组间肺部进一步复发/进展率相似(p = 0.97)。Kaplan-Meier分析显示,单纯肺转移患者的3年总生存率为73%,多发肺转移患者为40%,EPM患者为23% (p = 0.097)。结论:虽然复发性EWS患者的生存率较低,但局限于肺部的孤立复发患者往往是肺转移切除术的良好候诊者,并且在改善生存结果方面具有非统计学意义的显著趋势。
{"title":"Current management of pulmonary relapse in Ewing sarcoma: A report from the Pediatric Surgical Oncology Research Collaborative","authors":"Audra J. Reiter ,&nbsp;Lynn Huang ,&nbsp;Jennifer H. Aldrink ,&nbsp;Brian T. Craig ,&nbsp;Andrew M. Davidoff ,&nbsp;Lindsay J. Talbot ,&nbsp;Jordan Coggins ,&nbsp;Jasmine Smith ,&nbsp;Katherine C. Bergus ,&nbsp;Taleen A. MacArthur ,&nbsp;Stephanie F. Polites ,&nbsp;Roshni Dasgupta ,&nbsp;Chloe Boehmer ,&nbsp;Joseph Brungardt ,&nbsp;Marcus M. Malek ,&nbsp;Hannah N. Rinehardt ,&nbsp;Zachary J. Kastenberg ,&nbsp;Cameron M. Arkin ,&nbsp;Antoine Gourmel ,&nbsp;Nelson Piche ,&nbsp;Timothy B. Lautz","doi":"10.1016/j.phoj.2024.11.105","DOIUrl":"10.1016/j.phoj.2024.11.105","url":null,"abstract":"<div><h3>Background</h3><div>Relapse occurs in 30–40 % of patients with localized Ewing sarcoma (EWS). Our objective was to describe the current management and outcomes of patients with initially localized EWS who experience first pulmonary relapse.</div></div><div><h3>Methods</h3><div>This multi-center retrospective cohort study included patients ≤22 years old with initially localized EWS treated from 2007 to 2020 at 19 Pediatric Surgical Oncology Research Collaborative institutions, who developed pulmonary relapse. Kaplan-Meier analysis was performed.</div></div><div><h3>Results</h3><div>Thirty-three patients with initially localized EWS developed pulmonary relapse at a median age of 17 (IQR 14; 20) years. Eleven (33 %) patients also had extra-pulmonary metastases (EPM) at relapse. Among the 22 (67 %) patients with pulmonary-only relapse, 10 (45 %) had solitary pulmonary nodules. Pulmonary metastasectomy was performed in 8/10 (80 %) patients with solitary pulmonary-only metastases, 5/12 (42 %) patients with multiple pulmonary-only metastases, and 2/11 (18 %) patients who also had EPM. Whole lung irradiation was administered in 7/10 (70 %) with solitary pulmonary-only metastases, 7/12 (58 %) with multiple pulmonary-only metastases, and 2/11 (18 %) with EPM. Rates of further pulmonary relapse/progression were similar between groups (p = 0.97). In Kaplan-Meier analysis, 3-year overall survival was 73 % with solitary pulmonary-only metastases, 40 % with multiple pulmonary-only metastases, and 23 % with EPM (p = 0.097).</div></div><div><h3>Conclusions</h3><div>While survival for patients with relapsed EWS is poor, the subset of patients with solitary relapse confined to the lung are often good candidates for pulmonary metastasectomy and have a non-statistically significant trend towards improved survival outcomes.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"10 1","pages":"Pages 20-23"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143683013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of vitamin D deficiency in pediatric patients with sickle cell disease: A systematic review 儿童镰状细胞病患者维生素D缺乏症的患病率:一项系统综述
Pub Date : 2025-03-01 DOI: 10.1016/j.phoj.2025.02.001
Thiago de Souza Vilela , Mauro Fisberg , Gerson Ferrari , Josefina Aparecida Pellegrini Braga
Hypovitaminosis D is significantly more prevalent in sickle cell disease (SCD) compared to healthy control patients. The absence of adequate vitamin D levels in patients with a chronic inflammatory condition may exacerbate inflammation, worsening the disease. Therefore, a systematic review was conducted analyzing articles from the Medline database of the National Institute of Medicine between April 2023 and November 2023. Inclusion criteria were observational studies in pediatric populations up to 20 years old, published in English. Intervention studies, clinical trials, abstracts, and reviews were excluded. The final number of selected articles was 18 of 85 listed. The overall frequency of vitamin D deficiency in the pediatric age group with SCD was 50.49 % (569 out of 1127), considering 20 ng/mL (50 nmol/L) as the cutoff for deficiency, the most commonly used reference level for vitamin D deficiency in the listed studies. The prevalence of vitamin D deficiency in this population appeared to be higher when compared to children and adolescents without SCD. Our review concluded that vitamin D deficiency is prevalent in the pediatric population with SCD, but future studies should confirm the implications of this finding.
与健康对照患者相比,镰状细胞病(SCD)中维生素D缺乏症明显更普遍。慢性炎症患者缺乏足够的维生素D水平可能会加剧炎症,使疾病恶化。因此,我们对2023年4月至2023年11月来自美国国家医学研究所Medline数据库的文章进行了系统评价。纳入标准是针对20岁以下儿童人群的观察性研究,以英文发表。排除干预研究、临床试验、摘要和综述。最终入选的85篇文章中有18篇。考虑将20 ng/mL (50 nmol/L)作为缺乏症的临界值,在上述研究中最常用的维生素D缺乏症参考水平,SCD儿童年龄组中维生素D缺乏症的总体发生率为50.49%(569 / 1127)。与没有SCD的儿童和青少年相比,这一人群中维生素D缺乏症的患病率似乎更高。我们的综述得出结论,维生素D缺乏症在儿童SCD患者中普遍存在,但未来的研究应该证实这一发现的意义。
{"title":"Prevalence of vitamin D deficiency in pediatric patients with sickle cell disease: A systematic review","authors":"Thiago de Souza Vilela ,&nbsp;Mauro Fisberg ,&nbsp;Gerson Ferrari ,&nbsp;Josefina Aparecida Pellegrini Braga","doi":"10.1016/j.phoj.2025.02.001","DOIUrl":"10.1016/j.phoj.2025.02.001","url":null,"abstract":"<div><div>Hypovitaminosis D is significantly more prevalent in sickle cell disease (SCD) compared to healthy control patients. The absence of adequate vitamin D levels in patients with a chronic inflammatory condition may exacerbate inflammation, worsening the disease. Therefore, a systematic review was conducted analyzing articles from the Medline database of the National Institute of Medicine between April 2023 and November 2023. Inclusion criteria were observational studies in pediatric populations up to 20 years old, published in English. Intervention studies, clinical trials, abstracts, and reviews were excluded. The final number of selected articles was 18 of 85 listed. The overall frequency of vitamin D deficiency in the pediatric age group with SCD was 50.49 % (569 out of 1127), considering 20 ng/mL (50 nmol/L) as the cutoff for deficiency, the most commonly used reference level for vitamin D deficiency in the listed studies. The prevalence of vitamin D deficiency in this population appeared to be higher when compared to children and adolescents without SCD. Our review concluded that vitamin D deficiency is prevalent in the pediatric population with SCD, but future studies should confirm the implications of this finding.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"10 1","pages":"Pages 42-47"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143704653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thalassemia major due to compound heterozygous Codon 8/9 (+G) mutation with Dutch beta° thalassemia deletion 主要的地中海贫血是由于复合杂合密码子8/9 (+G)突变与荷兰β°地中海贫血缺失
Pub Date : 2025-03-01 DOI: 10.1016/j.phoj.2024.11.120
Dolat Singh Shekhawat , Tanuja Rajial , Siyaram Didel , Abhishek Purohit , Kuldeep Singh
{"title":"Thalassemia major due to compound heterozygous Codon 8/9 (+G) mutation with Dutch beta° thalassemia deletion","authors":"Dolat Singh Shekhawat ,&nbsp;Tanuja Rajial ,&nbsp;Siyaram Didel ,&nbsp;Abhishek Purohit ,&nbsp;Kuldeep Singh","doi":"10.1016/j.phoj.2024.11.120","DOIUrl":"10.1016/j.phoj.2024.11.120","url":null,"abstract":"","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"10 1","pages":"Pages 48-50"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management outcomes of South African children diagnosed with neuroblastoma in adolescence 南非青少年被诊断为神经母细胞瘤儿童的治疗结果
Pub Date : 2025-01-02 DOI: 10.1016/j.phoj.2024.12.003
Van Heerden Jaques , Esterhuizen Tonya , Du Plessis Jan , Geel Jennifer , Büchner Ané , Van Zyl Anel , Hendricks Marc , Naidu Gita , van Emmenes Barry , Vaithilingum M , Kruger Mariana

Background

Neuroblastoma (NB) is an indolent disease in adolescents. Only 5 % of neuroblastoma diagnoses are made in adolescents and adults. Limited data exists on Africans of older age groups.

Objectives

We aimed to compare the characteristics and outcomes of South African children ≥10 years diagnosed with NB with international reports.

Patients and methods

Multicentric, retrospective data of South African patients (0–15 y) with NB diagnosed between January 2000 and December 2016 were analyzed. Clinical profiles and outcomes of adolescents (≥10 years) with NB were compared to those of the younger patients in our cohort. The outcomes of adolescents (≥10 years) with NB were compared with those reported in the global literature.

Results

Thirty adolescents with a male-to-female ratio of 1:0.6 were diagnosed with NB, constituting 6.5 % of all patients with NB. Metastatic disease at diagnosis was present in 24 (75 %), including lung metastases in 2 (6 %). Half of the patients presented with a raised lactate dehydrogenase (LDH) and/or ferritin and unfavorable pathology.
Post-induction remission rates were higher in the adolescent group (33 %) compared to the 18–59 months (24.8 %) and 5–9.9 years (29.7 %) cohorts but less than the <18 months (47.2 %) cohort (p < 0.001). The adolescent group had the poorest five-year overall survival (20.9 %) compared to the children <18 months (39.0 %), 18–59 months (44.1 %), or 5–9.9 years old (63.5 %) (p < 0.001).

Conclusions

Despite a favorable response rate to induction chemotherapy, the five-year overall survival of adolescents with NB is dismal in South Africa.
神经母细胞瘤(NB)是青少年中一种惰性疾病。只有5%的神经母细胞瘤被诊断为青少年和成人。关于非洲老年人的数据有限。我们的目的是比较南非≥10岁诊断为NB的儿童与国际报告的特征和结局。患者和方法对2000年1月至2016年12月诊断为NB的南非患者(0-15岁)的多中心回顾性数据进行分析。将青少年(≥10岁)NB患者的临床资料和结果与我们队列中年轻患者的临床资料和结果进行比较。将青少年(≥10岁)患NB的结果与全球文献报道的结果进行比较。结果30例青少年诊断为NB,男女比例为1:6 .6,占所有NB患者的6.5%。诊断时出现转移性疾病24例(75%),其中肺转移2例(6%)。一半的患者表现为乳酸脱氢酶(LDH)和/或铁蛋白升高和不良病理。青少年组诱导后缓解率(33%)高于18 - 59个月组(24.8%)和5-9.9年组(29.7%),但低于18个月组(47.2%)(p <;0.001)。与儿童18个月(39.0%)、18 - 59个月(44.1%)和5-9.9岁(63.5%)相比,青少年组的5年总生存率(20.9%)最低(p <;0.001)。结论:尽管诱导化疗有良好的应答率,但南非青少年NB的5年总生存率很低。
{"title":"Management outcomes of South African children diagnosed with neuroblastoma in adolescence","authors":"Van Heerden Jaques ,&nbsp;Esterhuizen Tonya ,&nbsp;Du Plessis Jan ,&nbsp;Geel Jennifer ,&nbsp;Büchner Ané ,&nbsp;Van Zyl Anel ,&nbsp;Hendricks Marc ,&nbsp;Naidu Gita ,&nbsp;van Emmenes Barry ,&nbsp;Vaithilingum M ,&nbsp;Kruger Mariana","doi":"10.1016/j.phoj.2024.12.003","DOIUrl":"10.1016/j.phoj.2024.12.003","url":null,"abstract":"<div><h3>Background</h3><div>Neuroblastoma (NB) is an indolent disease in adolescents. Only 5 % of neuroblastoma diagnoses are made in adolescents and adults. Limited data exists on Africans of older age groups.</div></div><div><h3>Objectives</h3><div>We aimed to compare the characteristics and outcomes of South African children ≥10 years diagnosed with NB with international reports.</div></div><div><h3>Patients and methods</h3><div>Multicentric, retrospective data of South African patients (0–15 y) with NB diagnosed between January 2000 and December 2016 were analyzed. Clinical profiles and outcomes of adolescents (≥10 years) with NB were compared to those of the younger patients in our cohort. The outcomes of adolescents (≥10 years) with NB were compared with those reported in the global literature.</div></div><div><h3>Results</h3><div>Thirty adolescents with a male-to-female ratio of 1:0.6 were diagnosed with NB, constituting 6.5 % of all patients with NB. Metastatic disease at diagnosis was present in 24 (75 %), including lung metastases in 2 (6 %). Half of the patients presented with a raised lactate dehydrogenase (LDH) and/or ferritin and unfavorable pathology.</div><div>Post-induction remission rates were higher in the adolescent group (33 %) compared to the 18–59 months (24.8 %) and 5–9.9 years (29.7 %) cohorts but less than the &lt;18 months (47.2 %) cohort (p &lt; 0.001). The adolescent group had the poorest five-year overall survival (20.9 %) compared to the children &lt;18 months (39.0 %), 18–59 months (44.1 %), or 5–9.9 years old (63.5 %) (p &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Despite a favorable response rate to induction chemotherapy, the five-year overall survival of adolescents with NB is dismal in South Africa.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"10 1","pages":"Pages 9-16"},"PeriodicalIF":0.0,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143164846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric autoimmune hemolytic anemia – The good, bad and ugly! 小儿自身免疫性溶血性贫血-好的,坏的和丑陋的!
Pub Date : 2025-01-01 DOI: 10.1016/j.phoj.2025.100526
Shakambaree Prusty, Vandana Bharadwaj, Somdipa Pal, M., Jyothi, Sidharth Totadri, Anand Prakash
{"title":"Pediatric autoimmune hemolytic anemia – The good, bad and ugly!","authors":"Shakambaree Prusty,&nbsp;Vandana Bharadwaj,&nbsp;Somdipa Pal,&nbsp;M., Jyothi,&nbsp;Sidharth Totadri,&nbsp;Anand Prakash","doi":"10.1016/j.phoj.2025.100526","DOIUrl":"10.1016/j.phoj.2025.100526","url":null,"abstract":"","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"10 4","pages":"Article 100526"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145537308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unlocking Pandora’s box: Phenotypic diversity and genotypic correlation in pediatric rare anemias 打开潘多拉的盒子:儿童罕见贫血的表型多样性和基因型相关性
Pub Date : 2025-01-01 DOI: 10.1016/j.phoj.2025.100527
Minal Soneji, Anwesha Singh, Ritika Khurana, Purva Kanvinde, Minnie Bodhanwala, Sangeeta Mudaliar
{"title":"Unlocking Pandora’s box: Phenotypic diversity and genotypic correlation in pediatric rare anemias","authors":"Minal Soneji,&nbsp;Anwesha Singh,&nbsp;Ritika Khurana,&nbsp;Purva Kanvinde,&nbsp;Minnie Bodhanwala,&nbsp;Sangeeta Mudaliar","doi":"10.1016/j.phoj.2025.100527","DOIUrl":"10.1016/j.phoj.2025.100527","url":null,"abstract":"","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"10 4","pages":"Article 100527"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145537309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pediatric Hematology Oncology Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1